30-week, placebo-controlled, phase 3study in subjects with type 2 diabetes fail-ing to achieve glycemic control with met-formin, the 10-/H9262 g exenatide b.i.d. arm had signiÔ¨Åcant placebo-adjusted reduc-tions of /H110020.9% in A1C and /H110022.5 kg in weight at week 30 (35). Importantly, exenatide treatment was